NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $68.18 +2.39 (+3.63%) As of 11:10 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARWR alerts:Sign Up Key Stats Today's Range$67.00▼$68.9150-Day Range$65.79▼$89.5952-Week Range$29.81▼$95.49Volume930,726 shsAverage Volume2.29 million shsMarket Capitalization$9.60 billionP/E RatioN/ADividend YieldN/APrice Target$99.15Consensus RatingModerate Buy Company Overview Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. The company uses RNA interference (RNAi), a biological process that reduces the production of specific proteins, to target conditions that may be difficult to treat with conventional drugs. Arrowhead’s proprietary TRiM platform is designed to deliver RNAi-based therapies to different tissues, including the liver, lungs and other organs. Its investigational pipeline has included candidates for cardiovascular and metabolic diseases, liver disorders, pulmonary conditions and inflammatory diseases. Programs have targeted proteins such as apolipoprotein C-III, angiopoietin-like 3 and other disease-associated genes. The company’s drug candidates remain subject to clinical testing and regulatory review. Founded in 2003 and headquartered in Pasadena, California, Arrowhead conducts research and development activities through its own programs and collaborations with pharmaceutical companies. Its partners have included major international drugmakers, providing the company with access to broader development and commercialization capabilities in markets around the world. Christopher Anzalone serves as Arrowhead’s president and chief executive officer.AI Generated. May Contain Errors. Read More Arrowhead Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreARWR MarketRank™: Arrowhead Pharmaceuticals scored higher than 57% of companies evaluated by MarketBeat, and ranked 433rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 10 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArrowhead Pharmaceuticals has a consensus price target of $99.15, representing about 50.7% upside from its current price of $65.79.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($3.62) to ($4.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -29.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -29.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 18.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arrowhead Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.94% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 8.81.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 2.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.50 News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Arrowhead Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest8 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows6 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,186,600.00 in company stock.Percentage Held by Insiders3.60% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARWR Stock News HeadlinesNot a 'gangbusters launch' — Arrowhead predicts slow burn to $3-$4B peak for Redemplo, highlights 'massive pipeline'September 16 at 3:04 PM | msn.comARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?September 16 at 10:03 AM | finance.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 17 at 1:00 AM | Profits Run (Ad)ARWR stock on track for worst day in over a year despite positive early-stage data for cholesterol drug — retail dismisses 'sell the news' reactionSeptember 15 at 6:26 PM | msn.comArrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15 at 3:00 PM | seekingalpha.comArrowhead Pharmaceuticals Announces Interim Topline Clinical Data for Aro-Dimer-Pa Phase 1/2A Clinical TrialSeptember 15 at 1:25 PM | marketscreener.comMArrowhead Pharmaceuticals Stock Falls 9% After Announcement Of ARO-DIMER-PA Trial DataSeptember 15 at 1:25 PM | rttnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Director Adeoye Olukotun Sells 2,000 Shares of StockAugust 21, 2026 | insidertrades.comSee More Headlines ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $66.39 at the start of the year. Since then, ARWR stock has decreased by 0.9% and is now trading at $65.79. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Tuesday, August, 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.13. The firm's quarterly revenue was up 171.0% on a year-over-year basis. Read the conference call transcript. Who are Arrowhead Pharmaceuticals' major shareholders? Top institutional shareholders of Arrowhead Pharmaceuticals include BlackRock Inc. (10.53%), Jupiter Topco LLC (0.87%), Bank of New York Mellon Corp (0.61%) and Connor Clark & Lunn Investment Management Ltd. (0.44%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Daniel Joseph Apel, Martin Javier San, Douglas B Given, Tracie Oliver, Michael S Perry, Mauro Ferrari, William D Waddill, Hongbo Lu, Victoria Vakiener and Adeoye Y Olukotun. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX). Company Calendar Last Earnings8/04/2026Today9/17/2026Fiscal Year End9/30/2026Next Earnings (Estimated)11/24/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ARWR's financial health is in the Green zone, according to TradeSmith. ARWR has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARWR CIK879407 Webwww.arrowheadpharma.com Phone(626) 696-4702Fax626-304-3401Employees711Year Founded2001Price Target and Rating Average Price Target for Arrowhead Pharmaceuticals$99.15 High Price Target$126.00 Low Price Target$46.00 Potential Upside/Downside+46.4%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.63 million Net Margins-47.79% Pretax Margin-37.65% Return on Equity-60.06% Return on Assets-17.37% Debt Debt-to-Equity Ratio1.77 Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual Sales$829.45 million Price / Sales11.50 Cash Flow$0.11 per share Price / Cash Flow591.87 Book Value$3.64 per share Price / Book18.60Miscellaneous Outstanding Shares140,860,000Free Float135,786,000Market Cap$9.54 billion OptionableOptionable Beta1.28 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ARWR) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts